BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Viatris

Maybe the market is about to crash, and maybe it isn't. These stocks look like good picks either way.

3 Stocks to Buy Whether or Not a Market Crash Is Near

Recipients of two doses of the Pfizer vaccine have strong protection against the delta variant that has been linked to rising coronavirus figures in the U.S., according to a study published this week.

Pfizer vaccine 88% effective against delta variant: study

Pharma-Park Marburg, where German drugmaker BioNTech produces its COVID-19 vaccine, has been put up for sale in a potential 450 million euro ($531 million) deal, three people close to the matter said.

German Pharma-Park Marburg, home to BioNTech, up for sale -sources

Johnson & Johnson

Moderna

Coronavirus variants will be the key variable.

How Big of an Impact Will COVID-19 Have on the Stock Market Going Forward?

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have struck a deal with South Africa's Biovac Institute to process and distribute over 100 million doses a year of their COVID-19 vaccine for the African Union beginning in 2022. Technical transfer, on-site development, and equipment installation activities will begin immediately.

Pfizer/BioNTech Strike COVID-19 Manufacturing Deal With Biovac For South Africa

Shares of Pfizer Inc. gained 0.5% in premarket trading on Wednesday after the company and its COVID-19 partner BioNTech SE signed a deal with a South African drug maker to produce and distribute their shot in the African Union. BioNTech's stock was up 0.3%.

Pfizer, BioNTech partner with South African drug maker to make and distribute COVID-19 shot in Africa

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. Biovac will perform manufacturing and distribution activities within Pfizer's and BioNTech's global COVID-19 vaccine supply chain and manuf

Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa

Co-Diagnostics

Novavax

Vaxart

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Why Coronavirus Stocks Are Zooming Higher Today

An increasing amount of variants should sustain vaccine revenues well into late FY 2022 - early FY 2023. BioNTech's mRNA technology is at the heart of the future of vaccine creation.

BioNTech: Cheap, But Future Is Still In Question

CyberArk Software

Vertex Pharmaceuticals

BJ`s Wholesale Club Holdings Inc

Five9

Talkspace

Wix.com

Acceleron Pharma

With the trading day closing in on the halfway point, traders were feeling the heat as all the major indexes were ripping downward.

BioNTech, CyberArk, Vertex Pharma and More Monday Afternoon Analyst Calls

The COVID vaccine plays have showered investors with wonderful gains over the past eighteen months. The good times seem poised to expand due to unfortunate flare-ups of the global pandemic.

BioNTech: My Favorite Disaster/COVID Hedge

Pfizer Inc. said Friday that the Food and Drug Administration accepted its application for full approval of the COVID-19 vaccine it developed with BioNTech SE . As part of the application process, the FDA sets a decision date based on the rules of the Prescription Drug User Fee Act for applications that receive what is called Priority Review.

Pfizer says FDA's decision to approve its COVID-19 vaccine is expected by January

Gilead Sciences

Shares of BioNTech SE were down 2.4% in premarket trading on Monday after the company said it plans to buy one of Gilead Sciences Inc.'s clinical manufacturing facilities and its platform for T-cell receptor therapies. The companies did not disclose financial terms of the deal, saying only that BioNTech will make a one-time payment for the platform and the facility in Gaithersburg, MD.

BioNTech to buy T-cell receptor facility and platform from Gilead Sciences

BioNTech said it was acquiring a production site and a research and development platform from a subsidiary of U.S. biotech company Gilead to expand its footprint in north America and in novel cancer treatments.

BioNTech strengthens cancer therapy expertise with U.S. acquisition

MAINZ, Germany & SANTA MONICA, Calif.--(BUSINESS WIRE)--BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite's solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will comple

BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

It's the most likely winner benefiting from the most likely reason that an imminent crash might occur.

This Stock Should Soar If the Stock Market Crashes This Summer

The company received some very inspiring news from a top regulator.

Why BioNTech Is Blasting Higher Today

The FDA has granted priority review designation for Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) full approval application of their partnered COVID-19 vaccine, putting it on track for potential full approval by early next year. The goal date for a decision is January 2022.

Pfizer - BioNTech COVID-19 Vaccine Granted Priority Review By FDA

The first week of earnings season wraps up with major indices closely tracking the bond market in Wall Street's version of “follow the leader.” Earnings absolutely matter, but right now the Fed's policies are maybe a bigger influence.

Vaccine Stocks Climb After Moderna Added To S&P 500, With BioNTech Also Up

A new Hong Kong study has found that people fully vaccinated with the BioNTech SE (NASDAQ: BNTX) COVID-19 shot have ten times higher antibody concentrations than those who have received inactivated vaccines like China's Sinovac Biotech Ltd (NASDAQ: SVA), according to a new study published in The Lancet. Sinovac shot generated levels of the virus-targeting proteins that were “similar or lower” than the naturally occurring ones seen in recovered patients.

Lancet Study Shows BioNTech COVID-19 Vaccine Generates 10X Higher Antibody Levels Compared to Sinovac Shot

The global tally for the coronavirus-borne illness climbed above 188.9 million on Friday, while the death toll climbed further above 4.06 million, according to data aggregated by Johns Hopkins University. The U.S. leads the world with a total of 33.9 million cases and in deaths with 608,400 as the highly infectious delta variant continues to spread fast, especially in states with low vaccination rates.

Coronavirus tally: Global cases of COVID-19 near 189 million; BioNTech vaccine sees 10 times more antibodies than Sinovac one in study

Healthcare workers in Hong Kong who received the COVID-19 vaccine from BioNTech showed ten times more antibodies than those who received China's vaccine Sinovac, according to a study published in The Lancet Microbe on Thursday. "The difference in concentrations of neutralising antibodies identified in our study could translate into substantial differences in vaccine effectiveness," according to the research.

BioNTech COVID-19 vaccine antibodies ten times higher than Sinovac's: study

Should Investors Worry About the Pfizer-BioNTech Vaccine's Lower Efficacy Against the Delta Variant?

While antibodies are not the only measure of a vaccine's effectiveness the study likely adds to the growing pool of evidence that mRNA vaccines may offer more robust protection.

Pfizer's Covid-19 Vaccine Generated 10 Times More Antibodies Than China's Sinovac Shot, Hong Kong Study Shows

Pfizer has indicated that a third dose of its vaccine may be needed within six to 12 months after full vaccination, as initial immunity wanes and as new and more aggressive variants of the Coronavirus continue to spread. The company says that it has preliminary data to prove that an additional dose.

News for BioNTech SE Stock (BNTX)